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Abstract
Here, we review 15 years of clinical use of sirolimus in our transplant center, in context with the developing
immunosuppressive strategies use worldwide. The majority of studies were conducted in de novo kidney transplant
recipients, using sirolimus (SRL) in combination with calcineurin inhibitors (CNIs). We also explored steroid (ST) or
CNI-sparing therapies, including CNI minimization, elimination, or conversion strategies in combination with
mycophenolate (MMF/MPS). Pooled long-term outcomes were comparable with those obtained with CNI and
antimetabolite combination. Surprisingly, there are still several areas that need further investigation to improve the
risk/benefit profile of SRL in kidney transplantation, including pharmacokinetic/pharmacodynamic drug-to-drug
interaction with cyclosporine (CsA) or tacrolimus (TAC), mechanisms of SRL-associated adverse reactions and
combinations with other drugs such as belatacept and once-daily TAC, possibly leading to improved long-term
adherence. These studies, along with others investigating the benefits of SRL associated lower viral infections and
malignancies, are essential as we do not expect the introduction of new immunosuppressive drugs in the near
future.
Introduction
Beginning on June 1999, we started exploring alternative
immunosuppressive regimens using sirolimus (SRL). We
began our experience by combining SRL with progres-
sive reduction in cyclosporine (CsA) exposure in de
novo kidney transplant recipients. This initial experience
was followed by studies exploring SRL exposures com-
bined with reduced CsA exposure in black patients, early
CsA minimization or elimination strategies and the use
of SRL in calcineurin inhibitor (CNI)-free regimens
combined with mycophenolate (MMF). With the in-
creasing use of tacrolimus (TAC) in de novo kidney
transplant recipients, we also conducted a head-to-head
comparison of SRL with MMF followed by another study
comparing steroid (ST) or TAC withdrawal in kidney
transplant recipients receiving de novo therapy with
SRL. Later, we began to explore conversion strategies, ei-
ther late or early conversions from CNI to SRL.
De novo kidney transplant recipients
In our first open-label randomized trial, we compared
the safety and efficacy of 2mg fixed daily doses of SRL
with 2 mg/kg fixed daily doses of azathioprine (AZA) in
living related renal allograft recipients receiving CsA and
ST [1]. Because first reports suggested the potentiation
of CsA nephrotoxicity by SRL [2, 3], we attempted to
implement a small reduction in CsA exposure. In this
study, CsA concentrations were lower in patients receiving
SRL compared to AZA from week 4 (247 vs. 309 ng/mL, p
= 0.04) to month 12 (143 vs. 188 ng/mL, p = 0.045). The in-
cidence of the primary composite endpoint (biopsy con-
firmed acute rejection, graft loss, or death) was lower in
SRL group at 3 months (0 vs. 17.1 %, p = 0.025) but not at
12 months (11.4 vs. 14.3 %, ns). The relatively small reduc-
tion in CsA exposure was associated with no difference in
mean serum creatinine at 12 months (1.8 ± 0.6 vs. 1.6 ±
0.6 mg/dL, p = 0.23) but the small sample size may not had
sufficient power to detect the small difference observed.
Therefore, we decided to expand our experience to reach
90 patients receiving 2mg fixed daily doses of SRL [4]. At
12 months, mean whole blood CsA trough concentrations
were 100 ng/mL in patients receiving SRL and 200 ng/mL
in patients receiving AZA. Retrospective analysis showed
that mean whole blood SRL trough concentrations
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increased from day 7 to months 1 and 12 (5.2 ± 3.1 vs. 7.5
± 3.6 vs. 8.4 ± 6.0 ng/mL, p <0.0001) with a tenfold interin-
dividual variability, ranging from 2.5 to 23.5 ng/mL. There
was no difference in 1-year composite efficacy endpoint
comparing SRL and AZA groups (18 vs. 20 %) or in the
incidence of biopsy-proven acute rejection (14.4 and
14.3 %). Importantly, even with higher sample size, we
were unable to detect difference in mean serum creatinine
(1.65 ± 0.46 vs. 1.60 ± 0.43 mg/dL, p = 0.48) or in mean
calculated creatinine clearances (61 ± 15 vs. 62 ± 13 mL/
min, p = 0.58) at 1 year. At that time, we concluded that
the use of SRL and reduced CsA exposure was effective in
preventing acute rejection and preserving allograft
function.
Brazil has a highly miscegenated population with Afri-
can ancestry that is at an increased risk for renal allo-
graft failure [5]. Knowing that studies had demonstrated
that black patients requires higher doses of SRL to achieve
comparable efficacy compared to the Caucasian popula-
tion [6], we designed a study to identify optimal thera-
peutic SRL concentrations in black kidney transplant
recipients receiving reduced CsA exposure and prednis-
one [7]. Black patients received CsA, ST, and 5mg fixed
doses of SRL till day 7 when they were randomized to
maintain whole blood SRL trough concentrations between
8 and 12 or 15 and 20 ng/mL. There was no difference in
mean whole blood CsA trough concentrations at months
1 (182 ± 86 vs. 162 ± 87 ng/mL) and 12 months (62 ± 43
vs. 59 ± 52 ng/mL). At 6 months, mean whole blood SRL
trough concentrations were 10.8 ± 5.8 vs. 18.0 ± 6.1 ng/mL
(p <0.001). The incidence of biopsy-proven acute rejec-
tion was higher in the lower SRL concentration group
(18 vs. 8 %). Mean calculated creatinine clearance was
higher in the lower SRL concentration group (64.5 ± 17 vs.
54.4 ± 14.7 mL/min, p = 0.011) despite higher incidence of
acute rejection. The incidence of post-transplant diabetes
mellitus was 13 % and no CMV disease was observed.
Higher SRL concentrations were associated with higher
efficacy but lower renal function, further emphasizing the
complex interaction between these two drugs [8].
To further investigate the interaction between SRL
and CsA, we performed a sequencial pharmacokinetic
study at days 7, 30, and 90 in kidney transplant recip-
ients receiving 2- or 5-mg fixed daily doses of SRL.
Both SRL and CSA showed moderate to high inter
(39 to 70 and 33 to 52 %) and intra (30 to 41 and 25
to 43 %) subject variability, respectively. A threefold
increase in SRL concentrations (4.7 to 14.3 ng/mL)
resulted in 37 % increase in mean CSA AUC (6,654
to 9,133 ng.h/mL, p = 0.007). Similarly, a 1.8-fold in-
crease in CSA concentrations (190 to 345.5 ng/mL)
resulted in 115 % increase in mean SRL AUC (199.8
to 428.9 ng.h/mL, p = 0.002). These results confirmed
the unpredictable and complex pharmacokinetic
interactions between SRL and CSA in kidney trans-
plant recipients [9].
In two phase II trials in patients receiving AZA/ST
[10] or MMF/ST [11] and no induction therapy,
higher incidence of acute rejection was observed in
those treated with SRL compared to those receiving
CsA. The lack of adequate efficacy of CNI-free regimens
without induction therapy, along with the complex syner-
gistic interaction between CsA and SRL, led to studies ex-
ploring elimination or minimization of CsA, to obtain
maximal early efficacy for the prophylaxis of acute rejec-
tion and prevention of long-term CsA-associated toxicities
[12, 13]. Our multicenter national phase 4, open-label,
randomized (1:1) trial conducted in nine centers investi-
gated the safety and efficacy of concentration-controlled
use of SRL and CsA followed by CsA minimization or
elimination beginning at week 13 [14]. At 12 months,
there were no differences in renal function (61.08 vs.
65.24 mL/min, p = 0.132), incidence of biopsy-confirmed
acute rejection (14.3 vs. 22.5 %, p = 0.152). There were no
differences in the overall rate of study-drug discontinu-
ation (32.4 vs. 36.3 %, p = 0.562) but more patients discon-
tinued because of lack of efficacy/graft loss in the CsA
elimination group (4.8 vs. 14.7 %, p = 0.018). In summary,
CsA minimization or elimination offers treatment options
for de novo renal allograft recipients [15, 16]. Although
few studies have systematically investigated the ideal CsA
exposure in combination with SRL, it has been suggested
that up to 80 % reduction can be used with even superior
efficacy compared to full CsA exposure, with or without
SRL [17].
The growing number of kidney transplant recipients
receiving TAC and MMF prompted us to compare it
with the combination of TAC and SRL [18]. Kidney
transplant recipients receiving TAC-based immunosup-
pressive regimen were randomized to receive fixed daily
doses of MMF (2 g/day) or SRL (one loading dose of
15 mg, 5 mg/day till day 7, and 2 mg/day thereafter)
without induction therapy. Mean whole blood TAC
concentrations among patients receiving MMF or SRL
were similar at 1 (10.4 ± 4.0 vs. 9.8 ± 3.2 ng/mL) and 12
(6.9 ± 2.3 vs. 7.1 ± 2.5 ng/mL) months. Mean plasma
mycophenolic acid (MPA) trough concentrations were
2.9 ± 1.7 and 3.6 ± 2.2 mg/L, and mean whole blood SRL
trough concentrations were 4.2 ± 1.8 and 6.6 ± 3.5 ng/
mL, at 1 and 12 months, respectively. No differences
were observed in the incidence of biopsy-confirmed
acute rejection (12 vs. 14 %, p = 1.000). Patients receiving
SRL showed higher mean serum creatinine (1.6 ± 0.5 vs.
1.4 ± 0.3 mg/dL, p = 0.007), higher proportion of patients
with proteinuria (52.0 vs. 10.7 %, p = 0.041), higher mean
urinary protein concentrations (0.3 ± 0.5 vs. 0.1 ± 0.2 g/
L, p = 0.012), higher mean cholesterol concentration
(217 vs. 190 mg/dL, p = 0.030), and higher proportion of
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patients prematurely discontinued from randomized
therapy (26 vs. 8 %, p = 0.031). Similar findings were
observed in large international multicenter trials [19,
20]. Similar to the CsA clinical experience, more recent
studies have shown that lower TAC concentrations
should be used combined with SRL [21] and that TAC
discontinuation in patients receiving SRL was associated
with increased incidence of acute rejection [22].
During mid-2000s, with the approval of the anti-IL-2R
blockers for induction therapy, several trials of ST or
CNI avoidance or withdrawal were conducted, all with
the purpose of improving long-term tolerability and
safety of immunosuppressive regimens. With the prem-
ise from previous studies, we decided to explore whether
SRL would be effective in CNI-free or ST-free regimen.
We first evaluated the efficacy and safety of two CNI-
free regimens in low-risk recipients of one haplotype
living-related kidney transplants [23]. Immunosuppres-
sion consisted of TAC, AZA, and ST vs. two doses of
daclizumab, MMF, and STvs. two doses of daclizumab,
MMF, SRL, and ST. At 12 months, the incidence of
BCAR was higher in patients receiving CNI-free regimes
(10.5 vs. 48.5 vs. 24.0 %, p <0.01, respectively). In
patients of black ethnicity, the incidence of acute rejec-
tion was higher in the MMF/ST group (25 vs. 83.3 vs.
20 %, p = 0.055), respectively. There were no differences
in mean calculated creatinine clearance at 12 months
(58.9 ± 14.0, 56.9 ± 16.4, 59.3 ± 21.4 mL/min). Overall
incidence of post-transplant diabetes mellitus (3.3 %)
and cytomegalovirus disease (4.3 %) was similar in all
groups. It was then clear that CNI-free regimen, with
MMF or SRL/MMF, would not sustain low rates of
acute rejection, as demonstrated in multicenter inter-
national trials [24–26].
Subsequently, we explored early discontinuation of
either CNI or ST. Recipients of first renal transplant re-
ceived SRL, TAC, and ST without induction therapy and
were randomized to undergo ST (SRL/TAC) or TAC
(SRL/ST) withdrawal 3 months after transplantation
[27]. Lower mean whole blood SRL trough concentra-
tion was observed in patients receiving SRL/TAC com-
pared to SRL/ST (11.5 ± 3.0 vs. 15.3 ± 4.5 ng/mL). No
differences were observed in the incidence of BCAR
(4.2 vs. 9.5 %). Mean calculated creatinine clearance was
comparable (60 ± 11.5 vs. 63.4 ± 10.5 mL/min), and no sig-
nificant differences were observed in the proportion of pa-
tients with proteinuria at 12 months (20 vs. 30.7 %, p =
0.629), respectively. We observed a higher incidence of
lymphocele or lymphorrhea (13 vs. 4.1 %), proteinuria (13
vs. 8.3 %), graft dysfunction (17.3 vs. 4.1 %), stomatitis
(30.4 vs. 8.3 %), headache (56.5 vs. 33.3 %), leucopenia (8.6
vs. 0 %), thrombocytopenia (8.6 vs. 4.1 %), dyslipidemia
(78.2 vs. 66.7 %), and CMV infection (4.3 vs. 0 %) in SRL/
ST group. The incidence of NODAT (10.6 %) was similar
between groups. Higher mean cholesterol concentration
was observed in the SRL/ST group (191.9 ± 63.3 vs.
241.6 ± 61.5 mg/dL, p = 0.019). Treatment discontinu-
ation due to adverse events occurred in 12.5 % of pa-
tients in SRL/TAC group and 21.7 % in SRL/ST group.
Within 12 months of observation, our study was unable
to detect any significant difference in major transplant
outcomes comparing CNI and ST elimination strat-
egies. In this context, a recent review concluded that the
benefits of minimizing immunosuppression, either ST or
CNI, must be weighed against the risks of precipitating
acute rejection or chronic allograft dysfunction [28].
These exploratory studies conducted in de novo
kidney transplant recipients allowed us to perform a 10-
year retrospective analysis of pooled data from patients
included in prospective randomized trials in de novo
kidney transplant recipients receiving CNI combined
with SRL (n = 329) or AZA/MMF (n = 124). We did not
observe differences in patient (89.1 vs. 91.1, p = 0.766),
graft (72.9 vs. 76.6 %, p = 0.709), and biopsy-confirmed
acute rejection-free (78.1 vs. 79.0 %, p = 0.976) survivals,
respectively. The incidence of CMV infection was lower
(6 vs. 11 %, p = 0.024), but treatment discontinuation
was higher among patients receiving SRL (66 vs. 31.5 %,
p <0.001), respectively. At 5 years, mean estimated glom-
erular filtration rates were comparable (57.4 ± 18.6 vs.
57.0 ± 19.2 mL/min, p = 0.111) but the proportion of
patients with proteinuria was higher among patients
receiving SRL (44 vs. 19 %, p <0.001), respectively [29].
Critical analysis
The interest for the clinical use of SRL and CNI in de
novo kidney transplant recipients has reduced since its
approval in early 2000. The basic reason behind this
observation is perhaps the lack of a thorough under-
standing of the interaction between these two drugs. Al-
though the pharmacokinetic interaction between SRL
and CsA was anticipated, high doses and concentrations
of both SRL and CsA or TAC were used initially, leading
to a disproportionally higher incidence of adverse events,
poor tolerability, and ultimately drug discontinuation.
Key adverse events of this drug combination have been
associated with higher concentrations of both drugs,
namely, wound healing [30] and inferior renal function
[31]. Not surprisingly, two registry analyses showed in-
ferior graft survival in patients receiving SRL combined
with CsA [32] or TAC [33].
Alternatively, CNI avoidance and withdrawal trials
were implemented to avoid or minimize this drug inter-
action. A recent systematic review and meta-analysis of
randomized controlled trials showed higher incidences
of acute rejection but superior renal functions with no
differences in patient or graft survival were observed at
1 year after transplantation [34]. Nevertheless, a registry
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analysis confirmed that a CNI-free immunosuppressive
regimen consisted of SRL/MMF combination was associ-
ated with inferior renal transplant outcomes compared
to CNI combined with SRL or MMF [35]. Two main
reasons emerge from this observation. First, SRL and
MMF share similar profile of adverse events such as
gastrointestinal and bone marrow toxicities. Second,
recent data have suggested the increased risk of acute
rejection or chronic antibody-mediated rejection in pre-
sents with suboptimal CNI exposure [28]. Therefore,
more studies exploring different drug concentrations are
needed to define proper doses of both drugs associated
with a more favorable short- and long-term efficacy/
safety profile [36]. Nevertheless, prospective trials are re-
quired to define therapeutic concentrations for both
drugs associated with best efficacy/toxicity ratios.
Conversion strategies
Our first experience with conversion from CNI to SRL
occurred during the Sirolimus Renal Conversion Trial
(CONVERT) [37]. This study explored late conversion,
mean time after transplantation of 37 months, from CNI
to SRL. The primary efficacy endpoint, Nankivell GFR in
the intent-to-treat (ITT) population 12 months after
randomization, was comparable (59.0 and 57.7 mL/min)
in the cohort of patients with baseline GFR more than
40 mL/min. Conversion was associated with no difference
in the incidence of acute rejection, increased urinary pro-
tein excretion, and a lower incidence of malignancy com-
pared with CNI continuation. Treatment discontinuation
was higher in SRL conversion versus CNI continuation
patients at 12 (15.7 vs. 9.5 %, respectively, p = 0.013) and
24 (25.8 vs. 20.0 %, p = 0.070) months. Superior renal
function was observed among patients who remained on
SRL through 12 to 24 months, particularly in the sub-
group of patients with baseline GFR more than 40 mL/
min and proteinuria less than or equal to 0.11.
Following the initial promising data of the Spare the
Nephron trial [38], we designed our multicenter, prospect-
ive, open-label, national trial with planned conversion
from TAC to SRL 3 months after kidney transplantation.
Of 297 patients initially treated with TAC, MPS, and ST,
283 patients reached 3 months of whom 97 were con-
verted to SRL, 107 were maintained on TAC, and 79 were
patients receiving TAC without criteria to undergo inter-
vention. There was no difference in the primary objective,
superior estimated glomerular filtration rate in the SRL
group at month 24 in the intention-to-treat population
(66.2 ± 25.3 vs. 70.7 ± 25.1mL/ min, p = .817). There was
also no difference in the severity of chronic sclerosing le-
sions scores in 24-month protocol biopsies. Higher mean
urinary protein-to-creatinine ratio (0.36 ± 0.69 vs. 0.15 ±
0.53, p = 0.03) and higher incidence of treated acute rejec-
tion between months 3 and 24 (13.4 vs. 4.7 %, p = 047)
were observed in SRL compared to TAC group [39]. Inter-
estingly, comparable results were observed in a multicen-
ter international trial with similar design [40].
Critical analysis
Late conversion from CNI to SRL has not been consist-
ently associated with significant improvement in renal
function. Nevertheless, the trials identified risk factors
associated with poor clinical therapeutic response, in-
cluding the level of renal function, proteinuria, and
structural damage [41]. Early conversion trials, while ex-
cluding patients with these risk factors, were associated
with loss of efficacy, lower tolerability and increased in-
cidence of adverse events. In one study, 192 kidney
transplant recipients receiving CsA, MMF, and ST were
converted to SRL (n = 95) at 3 months or continued CsA
(n = 97) and underwent planned ST discontinuation at
month 8 (CONCEPT) [42]. At 12 months, the incidence
of acute rejection was higher (17 vs. 8 %, p = 0.071) but
renal function was superior in patients converted to SRL
(68.9 vs. 64.4 mL/min/1.73 m2, p = 0.017) compared to
those maintained on CsA. Interestingly, the incidence of
subclinical inflammation in protocol biopsies performed
at 12 months (30.6 %) was higher in the SRL compared to
CsA group (45.2 vs. 15.3 %) and associated with lower
estimated glomerular filtration rate (50.8 ± 13.3 vs. 57.7 ±
16.3 mL/min/1.73 m2, p = 0.035) at 30 months [43].
Furthermore, no significant differences were observed in
the incidence of interstitial fibrosis comparing both groups
[44]. In an extension study, renal function was superior in
SRL (n = 77) compared to CsA (n = 85) group at
48 months (62.6 vs. 57.1 mL/min/1.73 m2, p = 0.013) [45].
Taken together, when choosing this immunosuppres-
sive strategy, one needs to balance the risks of early sub-
clinical and clinical rejection and the long-term benefits
of superior renal function. Better understanding of risk
factor for acute rejection, using more robust diagnostic
methods, may increase the success of these strategies.
Low tolerability may be associated with factors intrinsic
to the drug (aftous ulcers, dyslipidemia, peripheral
edema) but others emerge as a consequence of overlap-
ping toxicity profile of MPA and SRL [46]. Better part-
ners such as belatacept may improve the long-term
safety of SRL [47]. More studies aiming to investigate
SRL-associated proteinuria using different immunosup-
pressive strategies after kidney transplantation is essen-
tial to increase the safety of these regimens [48]. In this
direction, a multicenter prospective trial demonstrated
that the use of ramipril prior to early conversion from
CNI to SRL is associated with lower incidence of pro-
teinuria during the first 12 months [49].
The association of SRL with lower incidence of viral
infections is opened for various types of investigation
[50]. Significant reductions in the incidence of CMV
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[51] and BKV [52] infections have been reported in
patients receiving SRL. Cancers with higher relative inci-
dence among kidney transplant recipients compared to
the general population are associated with viral infection
such as Kaposi sarcoma (herpesvirus 8), non-Hodgkin
lymphomas (EBV), and skin cancer (HPV) [53]. The
association between SRL and lower incidence of cancer
will be explored in the future [54], as death due to can-
cer contributes increasingly to the overall death rate
among kidney transplant recipients (http://www.anzda-
ta.org.au/anzdata/AnzdataReport/31stReport/Ch10Can-
cerReport.pdf ). The association of SRL and reduced
recurrence of non-melanoma skin cancer was well docu-
mented in three independent international multicenter
trials [55–57]. Nevertheless, the benefit observed was
mitigated by the low tolerability of the SRL-containing
immunosuppressive regimen.
Future perspectives
It is surprising that even after 15 years of clinical use,
SRL-based immunosuppressive regimens are still evolv-
ing. More importantly, several areas of research are still
open for future studies. Comprehensive understanding
the complex pharmacokinetic and pharmacodynamics
interaction between SRL and CNI will be decisive to
investigate and define target concentrations for both
classes of drug, either in de novo or as a conversion
strategy. In experimental models, dose-dependent bio-
chemical metabolite patterns differences were observed
in the brain [58] and in the kidney [59] when combining
SRL or EVR with CsA, suggesting that SRL potentiates
CsA-induced mitochondrial dysfunction. Nevertheless,
whether this metabolic difference is translated into
measurable clinical differences in outcomes or renal
function is not known as there is no head-to-head com-
parison of these two drugs using CNI minimization
strategies. This will be even more important because
sotrastaurin [60, 61] and tofacitinibe [62] drug develop-
ment program were prematurely terminated and no new
drugs are expected to be approved for clinical use soon.
The effects of SRL in reducing the incidence of viral in-
fections and malignancies may influence transplant out-
comes as long as we increase safety and tolerability of
SRL-containing immunosuppressive regimens. Promis-
ing strategies include the combination of SRL with
once-daily TAC or belatacept. While the first once-daily
TAC formulation of TAC has already been used in the
clinical setting [63], a new formulation has finished
phase three trials and will soon be registered [64]. The
pharmacokinetics, efficacy, and safety of the combin-
ation of SRL with once a day TAC should be investigated
in future studies, including methods to measure the in-
fluence of adherence on transplant outcomes. A pilot
study in de novo kidney transplant recipients receiving
rabbit anti-thymocyte globulin and short course of ST
showed similar efficacy and 8–10 mL/min higher glom-
erular filtration rate at 12 months compared with TAC/
MMF [47]. Furthermore, while SRL has been associated
with increasing regulatory T cells [65], belatacept has
been associated with lower incidence of de novo donor-
specific antibodies [66]. In summary, although several
SRL-contained immunosuppressive strategies have
already been tested in solid organ transplantation over
the last 20 years, many more studies are needed to allow
our patients to fully benefit from this therapy in the
future.
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